Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A randomized, double-blind, placebo-controlled Phase 2 trial of MABT5102A in mild to moderate Alzheimer's disease
2010-021926-37Phase 2Completed
- Sponsor
- Genentech
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing MABT5102A with Placebo (2 arms). Primary endpoint: Change in ADAS-Cog (12-item) score from baseline to Week 73. Started Jan 2011; status: completed.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2010-021926-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021926-37.